1. Scott Huennekens

    0 Comments Leave a Comment

    1-15 of 115 1 2 3 4 5 6 7 8 »
    1. Mentioned In 115 Articles

    2. Distributed medical sensing system and method

      Distributed medical sensing system and method
      A method of communicating medical sensing data including receiving, at a patient communication system, medical sensing data collected by a medical sensing device during a medical sensing procedure. The method also includes creating, with the patient communication system, a data message, the data message including at least a portion of the medical sensing data, information about the medical sensing procedure, and information about the medical sensing data and transmitting, with ...
      Read Full Article
    3. Simultaneous Imaging, Monitoring, And Therapy

      Simultaneous Imaging, Monitoring, And Therapy
      Using the disclosed intravascular devices it is possible to image tissues, deliver therapy, and evaluate the tissue after the therapy is delivered. One embodiment is a catheter configured to provide ultrasound imaging, drug delivery, and Doppler flow analysis. The devices can use ultrasound imaging as well as optical coherence tomography (OCT).
      Read Full Article
    4. Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014

      Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014
      ... (Fractional Flow Reserve) businesses and an increase in European revenues of approximately 20 percent," said Scott Huennekens, president and chief executive officer. "Our business in the U.S. continued to be impacted by...
      Read Full Article
    5. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis

      Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis
      Volcano Corporation(Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the second quarter and first six months of 2013. For the quarter endedJune 30, 2013, Volcano reported revenues of$101.3 million, an increase of six percent on a reported basis versus the same period a year ago and ...
      Read Full Article
    6. Three dimensional co-registration for intravascular diagnosis and therapy

      Three dimensional co-registration for intravascular diagnosis and therapy
      A method and system are disclosed for creating, in a coordinated manner, graphical images of a body including vascular features from a combination of image data sources. The method includes initially creating an angiographic image of a vessel segment. The angiographic image is, for example, either a two or three dimensional image representation. Next, a vessel image data set is acquired that is distinct from the angiographic image data. The ...
      Read Full Article
    7. 1-15 of 115 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Scott Huennekens

    Scott Huennekens

    Scott Huennekens is President and CEO of Volcano Therapeutics. Scott Huennekens has served as our President and Chief Executive Officer and as a member of our board of directors since April 2002. From January 2000 to March 2002, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company. Mr. Huennekens holds a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard University.

  3. Quotes

    1. With respect to the planned Axsun divestiture, this decision was driven by our long-term strategy to focus on coronary imaging and physiology leadership, peripheral expansion, profitability and business scale. The Axsun business and financial model is no longer a strategic fit with Volcano. We greatly appreciate the significant contributions of the Axsun team to Volcano over the past several years.
      In Volcano Corporation to Divest Axsun and Settle All Ongoing Litigation with St. Jude
    2. We believe this reprioritization initiative better focuses and positions Volcano to compete more effectively in our growth markets.
      In Quite a Contrast: Volcano Corporation May Cancel its Intravascular OCT Product and St. Jude Medical Indicates $1B a Year Revenue Opportunity
    3. We will be reinvesting the savings from this reprioritization of resources in higher growth, lower risk revenue generating product and market development opportunities. These include peripheral, FFR and expanded distribution. We believe this reprioritization initiative better focuses and positions Volcano to compete more effectively in our growth markets,
      In Volcano Corporation Cancels its Intravascular OCT Development Program?
    4. The company had a solid third quarter marked by very strong growth in our peripheral IVUS (Intravascular Imaging) and our FFR (Fractional Flow Reserve) businesses and an increase in European revenues of approximately 20 percent.
      In Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014
    5. Sync-Rx's technology will allow Volcano to better integrate and present a wide variety of data in an intuitive manner that creates more meaningful information for the physician and documentation for the hospital...We see the technology being incorporated seamlessly into our existing multi-modality system with the ability in the future to co-register IVUS images directly on to the angiogram. Future applications for the Sync-Rx technology in other areas include co-registration of non-invasive imaging with real time intra-body physiology measurements and IVUS peripheral, forward looking IVUS, forward looking intra-cardiac (ICE), and OCT imaging.
      In Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.
    6. Axsun Industrial segment revenues, which were approximately $1.5 million in the fourth quarter of 2011 versus revenues of $5.1 million in the fourth quarter a year ago, or a decline of approximately 70 percent.
      In Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues
    7. We are delighted with our financial performance in 2010, which reflects the value of our multi-modality platform and the successful execution of sales, market development and clinical strategies to support our industry-leading technologies...we continued to drive market share gains and increased market penetration, and are now the market share leader for IVUS (Intravascular Ultrasound) in the U.S., Japan and Europe. In addition, our FM (Functional Measurement) business demonstrated strong growth with year-over year revenue increases of 33 percent and 49 percent for the fourth quarter and all of 2010, respectively...We completed our distribution transition with Fukuda in Japan during the quarter and are now serving 95 percent of our business in the market on a direct basis, which is driving growth in both revenues and operating margin.
      In Volcano Reports Record Revenue and GAAP Profitability for 2010
    8. After two-plus years of litigation, we are gratified by the Court's decision. Neither Volcano nor Axsun used any of LightLab's purported trade secrets in Volcano's development of its OCT System, or Axsun's OCT tunable laser...With LightLab's trade secret allegations now behind us, we will continue to focus our energy on developing key products that improve patient care.
      In Final Superior Court Ruling on Trade Secret Lawsuit Favors Volcano Corporation and Its Axsun Subsidiary
    9. We intend to continue developing our (optical coherence tomography) system, and can now do so with the reassurance that the court concurs with our position.
      In Volcano gets mixed decision in unfair competition case
    10. "We are pleased with this ruling. Along with prior court decisions issued in October 2010 and in December 2009, it confirms that that Volcano/Axsun are not using LightLab's purported trade secrets in our OCT development efforts. We intend to continue developing our OCT system, and can now do so with the reassurance that the Court concurs with our position. Volcano will continue to execute on our growth strategy of providing industry leading diagnostic and therapeutic imaging devices to improve patient outcomes"
      In Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case